GLP-1 drugs: Unexpected benefits and risks
In recent years, GLP-1 weight loss medications have become one of the most talked-about medical breakthroughs in obesity and diabetes treatment. Drugs like semaglutide and liraglutide are already widely known for helping people lose weight and improve blood sugar control. But now, new research suggests these medications may offer another major health advantage — reducing asthma flare-ups.
A new study presented at the prestigious European Congress on Obesity 2026 has found that people with asthma who used GLP-1 medications experienced significantly fewer asthma attacks and needed less rescue inhaler use.
This discovery could change how doctors think about treating asthma in people who also struggle with obesity or type 2 diabetes.
What Did the New Study Find?
Researchers from Copenhagen University Hospital analyzed health data from more than 27,000 adults living with asthma and either obesity, overweight, or type 2 diabetes.
The findings were impressive:
- Asthma exacerbations (serious asthma flare-ups) dropped by 26%
- Rescue inhaler use decreased by 14%
- Exposure to inhaled corticosteroids reduced by 23%
- Pneumonia events declined by 10%
These improvements were observed after patients started using GLP-1 receptor agonist medications.
The study included popular GLP-1 drugs such as:
- Semaglutide
- Liraglutide
- Dulaglutide
- Exenatide
Interestingly, the benefits were seen both in people with obesity and those with type 2 diabetes.
Why Are GLP-1 Drugs Helping Asthma?
Researchers believe weight loss plays a major role.
Obesity and asthma are closely connected. Excess body fat can increase inflammation throughout the body and make breathing more difficult. Many overweight individuals experience shortness of breath even without severe asthma symptoms.
When people lose weight, pressure on the lungs decreases, inflammation reduces, and breathing often improves naturally.
According to Dr. Kjell Erik Julius Håkansson, obesity creates a “pro-inflammatory state” in the body that may worsen asthma symptoms.
Scientists also believe GLP-1 medications may directly reduce airway inflammation, although more studies are needed to fully confirm this effect.
What Are GLP-1 Medications?
GLP-1 receptor agonists are medications originally developed to treat type 2 diabetes. Over time, doctors discovered that these drugs also help regulate appetite, reduce cravings, and support substantial weight loss.
Today, GLP-1 medications are widely prescribed for:
- Obesity management
- Type 2 diabetes
- Weight-related metabolic conditions
- Cardiovascular risk reduction
Some of the most recognized GLP-1 medications include:
- Ozempic
- Wegovy
- Saxenda
- Mounjaro
These medicines work by mimicking a natural hormone that controls hunger, insulin release, and digestion.
How the Study Was Conducted
The Danish research team used nationwide healthcare records to examine adults with asthma before and after starting GLP-1 treatment.
To make the study more accurate:
- Patients with severe COPD were excluded
- Individuals receiving expensive biologic asthma drugs were excluded
- Researchers compared asthma outcomes one year before and one year after GLP-1 use
The average age of participants was 54 years, and around 66% were women.
About half of the prescriptions involved liraglutide, while nearly 48% involved semaglutide.
Could This Change Asthma Treatment in the Future?
The findings are extremely promising, especially because asthma and obesity often occur together.
Doctors are increasingly recognizing that obesity-related asthma may behave differently from classic allergic asthma. Traditional asthma treatments sometimes work less effectively in overweight patients.
If future clinical trials confirm these results, GLP-1 medications could become part of a broader asthma management strategy for patients with obesity or metabolic disease.
This could potentially help reduce dependence on steroids, which are commonly used during asthma attacks but may cause side effects over time.
Why Reducing Steroid Use Matters
Asthma flare-ups are often treated with corticosteroids, either orally or intravenously. While these medications can save lives, repeated use may increase the risk of:
- Osteoporosis
- High blood sugar
- Weight gain
- Immune suppression
- Type 2 diabetes
A reduction in asthma attacks could therefore improve long-term health outcomes significantly.
Important Limitations of the Study
Although the results are encouraging, researchers also acknowledged some limitations.
The study did not have access to detailed clinical records such as:
- Actual body weight
- BMI changes
- Exact amount of weight lost
This means scientists cannot yet say with certainty whether the asthma improvements came directly from the medication itself or mainly from weight loss.
More controlled clinical trials will be needed in the future.
Growing Interest Beyond Weight Loss
The medical community is now discovering that GLP-1 medications may affect many systems in the body beyond appetite control.
Emerging research suggests possible benefits for:
- Heart disease
- Kidney health
- Fatty liver disease
- Sleep apnea
- Inflammation
- Brain health
The asthma findings add another exciting possibility to this rapidly growing field of research.
Final Thoughts
The latest research from Denmark offers fresh hope for millions of people living with both asthma and obesity.
A 26% reduction in asthma flare-ups is not a small improvement — it could mean fewer emergency visits, less steroid exposure, better breathing, and improved quality of life.
While more research is still needed, GLP-1 medications are increasingly proving that they may be much more than just weight-loss drugs.
As science continues to uncover their broader health benefits, these medications could reshape the future of chronic disease treatment in ways few expected just a few years ago.
#GLP1 #AsthmaRelief #WeightLossDrugs #Semaglutide #HealthResearch